Abstract Details

Title Endoplasmic Reticulum Stress exacerbate Stroke outcome in Chronic Kidney Disease

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P6 - Poster Session 6 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-002

Background Stroke is the second leading cause of disability and death worldwide with endoplasmic reticulum (ER) stress playing a crucial role in its pathology. Chronic-kidney disease (CKD) has been reported to be one of the major contributors for exacerbating stroke pathology. Impairment in cognition is one of outcomes of ischemic stroke. The underlying mechanism of ER-stress mediated cognition impairment in both CKD and stroke pathology has been explored limitedly.

Objective The study aims to decipher the possible molecular mechanism of post-stroke Endoplasmic Reticulum (ER)-stress mediated cognition impairment in chronic kidney disease (CKD) animals.

Design/Methods CKD was induced in male SD rats with 0.5% adenine diet for 28 days followed by a middle cerebral artery occlusion (MCAo) to generate ischemic stroke. Rats were evaluated for neurodeficit scores, motor functions and sacrificed after 24 hours for performing molecular studies. In another group of animals, a long-term study was performed for 28 days post-stroke to evaluate cognition changes. Brains were harvested for estimation of infarct size. Cortical brain regions were obtained for further biochemical and molecular studies.

Results Increased infarct region, neurodeficit scores and impaired motor function were observed in CKD+Stroke animals as compared to Sham, CKD and Stroke animals. Increased MDA and nitrite levels as well as decreased glutathione and SOD levels were observed in CKD+Stroke animals as compared to Sham, CKD and Stroke animals. Cognition impairment was higher in CKD+Stroke animals as compared to other animals. An increase in poshphorylated eIF2α, Caspase12, CHOP and decrease in myelin basic protein (MBP) were observed.

Conclusions ER stress following stroke in CKD may contribute towards exacerbating ischemic stroke pathology.

Authors/Disclosures
Pallab Bhattacharya, PhD (National Institute of Pharmaceutical Education and Research (NIPER),Ahmedabad.) PRESENTER	Dr. Bhattacharya has nothing to disclose.
	No disclosure on file
Deepaneeta Sarmah, M Pharm (National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A))	Miss Sarmah has nothing to disclose.
Antra Chaudhary, MS (Pharm) (National Institute of Pharmaceutical Education and Research (NIPER))	Ms. CHAUDHARY has nothing to disclose.
	No disclosure on file
	No disclosure on file
Debarati Ghosh (NIPER AHMEDABAD)	Ms. Ghosh has nothing to disclose.
Dileep R. Yavagal, MD, FAAN (University of Miami Miller School of Medicine)	Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line.